Rainer Fietkau, MD, on Pancreatic Cancer: Initial Trial Results on Sequential Chemotherapy and Chemoradiotherapy
2022 ASCO Annual Meeting
Rainer Fietkau, MD, of Germany’s University Hospital Erlangen, discusses phase III findings of the CONKO-007 trial, which examined the role of sequential chemotherapy and chemoradiotherapy administered to patients with nonresectable locally advanced pancreatic cancer following standard-of-care chemotherapy (Abstract 4008).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
So CONKO-007 study compared in a randomized Phase III trial the effect of chemoradiotherapy or chemotherapy following induction chemotherapy. We included the patients with nonresectable locally advanced pancreatic cancer. Following three months of induction therapy, restaging was performed and patients with new detected metastasis or insufficient dosage of chemotherapy were included. 525 patients were included. 366 patients were randomized.
Important, we had the following feature of the study. Nonresectability was confirmed a panel of five experienced surgeons. This was checked again following the whole therapy and surgery was recommended if an R0 resection seems to be possible. And, we succeeded, that in both arms about 36% of the patients were then treated with surgery. We think that this high number was due to the fact that surgery was often recommended in the second surgical evaluation.
The primary end point, the R0 resection, was evaluated in the 122 patients with resection. Following chemoradiotherapy, more R0 resections were possible. The rate of R1 resections was significantly lower. The OS rate of CRM negative tumor was significantly higher. Furthermore, we found significantly more complete remissions following chemoradiotherapy.
In a second analysis, for all randomized patients nearly all statistically different parameters remained significant. Complete remission rate, R1 resection rate, CRM positive or negative status, all in favor of chemoradiotherapy. Only the R0 resection rate was no more statistically different, but this did not translate into a better overall progression free survival or overall survival. But what is very important, is the effect of additional surgery. None of the patients without surgery survived five years, but 17.5% with additional surgery. Of course, these are no randomized data and are biased by patient selection, but it may show the important role of surgery of these patients.
Moreover, the best survival data we achieved for CRM or R0 resected patients was a five year survival rate of 35 to 27%. We found some hints that chemoradiotherapy improves this long term survival of surgically treated patients. Five year survival following chemoradiotherapy is 24% compared to 20% following chemotherapy alone. Of course, these results are not statistically different but may be a hint how the better R0 resection rate may potentially translate into a better survival.
In conclusion, we found that additional chemoradiotherapy to chemotherapy improves significantly the R0 resected rate, in surgically treated group but not in all randomized patients. Additional chemoradiotherapy improves the rate of R0 CRM negative resected significantly and very importantly, 36% of all randomized patients can be treated additionally with surgery, the five year survival of 17.5% compared to 0% without surgery. Overall this concept of induction chemotherapy, additional chemoradiotherapy and surgery, is visible, with a five year survival rate of 9.6% and selects a favorable subgroup of patients that has an impressive long term survival rate of up to 26%.
And the next steps in our analysis will be a further evaluation of prognostic parameters to select better patients who will benefit most from surgery and chemoradiotherapy.
Related Videos
The ASCO Post Staff
Thomas Powles, MD, PhD, of Barts Health NHS Trust, Queen Mary University of London, and Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, discuss the 24-month findings from the phase III EV-301 trial, which suggest that enfortumab vedotin-ejfv continues to show a significant and consistent survival advantage over standard chemotherapy in patients with previously treated advanced urothelial carcinoma (Abstract 4516).
Lisa A. Carey, MD, of the University of North Carolina Lineberger Comprehensive Cancer Center, and Hope S. Rugo, MD, of the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discuss phase III results from the TROPiCS-02 trial. This study showed that sacituzumab govitecan-hziy was more beneficial than single-agent chemotherapy in terms of progression-free survival in heavily pretreated patients with hormone receptor–positive/HER2-negative and unresectable advanced breast cancer (LBA1001).
The ASCO Post Staff
Gilberto de Lima Lopes, Jr, MD, MBA, of the Sylvester Comprehensive Cancer Center at the University of Miami, and Matthew Krebs, PhD, of The University of Manchester and The Christie NHS Foundation Trust, discuss results from the CHRYSALIS study. The trial showed that the bispecific antibody amivantamab-vmjw demonstrated antitumor activity, even after prior treatment, in patients with non–small cell lung cancer that exhibits the MET exon 14 skipping mutation (Abstract 9008).
The ASCO Post Staff
Sumanta K. Pal, MD, of City of Hope National Medical Center, discusses findings from the COSMIC-021 study, which showed that cabozantinib plus atezolizumab demonstrated encouraging clinical activity with manageable toxicity in patients with inoperable locally advanced or metastatic urothelial carcinoma. The combination was administered as first-line therapy in cisplatin-based chemotherapy–eligible and –ineligible patients and as second- or later-line treatment in those who received prior immune checkpoint inhibitors (Abstract 4504).
The ASCO Post Staff
Akihiro Ohba, MD, of Japan’s National Cancer Center Hospital, discusses phase II data from the HERB trial on fam-trastuzumab deruxtecan-nxki, which showed activity in patients with HER2-expressing unresectable or recurrent biliary tract cancer (Abstract 4006).